The deal secures Lakefront an initial 8.9 million dollars, with the potential for an additional 230 million dollars contingent on meeting future development milestones. Beyond the upfront cash, the agreement includes a low-single digit royalty structure on potential future products. This divestment follows a comprehensive strategic review initiated by Lakefront leadership to shed its cell therapy business units. By finalizing this transfer of assets, the company effectively concludes its exit from the space, clearing the path for its remaining corporate focus.
Lakefront Biotherapeutics Divests Cell Therapy Assets to Armed Cell
With an upfront payment of 8 million euros, Lakefront Biotherapeutics has offloaded its early-stage cell therapy pipeline to Netherlands-based Armed Cell Therapeutics BV. This transaction marks the final stage of a strategic wind-down, signaling the company's full retreat from its legacy research operations in the sector.
When reusing this material a link to Money Talk is required.
Comments (0)
No comments yet. Be the first!